Answers are grounded in this paper and cite their sources.
Much of the academic literature about cerebral palsy (CP) opens with a definition of the condition, closely followed by the statement ‘and prevalence has remained relatively stable’ at around 2 of 1000 live births. However, in recent times, there has been some evidence and discussions that ‘prevalence is decreasing and so too is severity’ 1, 2. Those working with people with CP cannot help but be buoyed by the idea that the impact of research, advances in obstetric and neonatal care, along with improved public awareness for healthy pregnancies may be contributing to reducing CP prevalence and disability severity. Could it be, that prevalence is not stable that there are in fact changes afoot? The epidemiology of CP is complex, and there are details, sometimes conflicting, that lie under important summary statements and take home messages. Nevertheless, epidemiologists should delve into the detail, discuss it with those working in the field and attempt to translate and disseminate the complexity for people with CP, their families, health professionals, service providers, policymakers, researchers and funders of research. The very fact that we are able to discuss the epidemiology of CP is entirely due to the work of long-standing CP Registers, which have robust methods and whose results have been published continually. Two very different regions of the world, with similar numbers of live births, have CP registers that fit these criteria: Western Australia (Western Australian Register of Developmental Anomalies, WARDA) and western Sweden. The most recent update from western Sweden is the 12th in their series 3 published in the current edition of Acta Paediatrica. These registers provide the best evidence to show us that changes in prevalence of CP are possible and that, in fact, CP prevalence may never have been stable. The first indicator comes from the fact that CP registers and surveillance programs report birth prevalence by combining two to four years of birth, because there is too much variation (especially within small populations) on a yearly basis. Even with these grouped birth years, neither the western Sweden nor Western Australian group has ever reported a plateauing of overall prevalence; rather the prevalence has been continually changing, moving, fluctuating up and down, between 1.4/1000 LBs and 2.5/1000 LBs over a 60-year period. The Western Australian data show similar patterns of fluctuations over the same period but, at an overall, higher rate. Instead of declines and increases, these small fluctuations in prevalence in the context of the many changes in medicine and public health over this period could still of course be described by some as ‘relatively stable’. In retrospect, the authors of the original Swedish CP epidemiology paper gave us a big clue when they titled their seminal paper in 1975 ‘The changing panorama of CP in Sweden 1954–1970. I. Analysis of the general changes’ 4. These words have been used in the western Sweden updates ever since. There seems to be no real evidence to say that prevalence has been stable. Perhaps we need to change our discourse around CP prevalence to ‘prevalence of CP has been continually shifting and changing’. So, if prevalence is not stable and it is continually changing, is prevalence currently decreasing for Sweden? When compared to births from 1992 to 2006, yes (although not statistically significantly), compared to the highs of 2.5/1000 LBs in the mid-1980s, yes definitely, but the answer would be ‘no’ if compared to the lows of the mid-1990s and in particular the mid-1960s to mid-1970s. This update also shows that CP following term births, by far the largest gestational age group numerically, is slowly decreasing from its most recent high point in the early 2000s. Along with this decrease, is a statistically significant decrease in dyskinetic CP and tetraplegia/quadriplegia, more severe subtypes of CP. We must celebrate these important wins along the way and learn from all the fluctuations, both up and down. Another argument to support the ‘continually changing prevalence’ concept is that there are many different aetiologies, risk factors and causal pathways that lead to CP that are also constantly changing and vary from region to region. Pathways come and go, particularly, once they are well defined and can be treated or prevented. Himmelmann and Uvebrant's paper 3 reports the good news that, between 2007 and 2010, there were no children with CP following kernicterus, once a small, but well-defined pathway to CP in high-income countries 5. It remains a pathway that needs to be continually monitored in high-income countries, as practices and immigration patterns change 6. What about other parts of the world? There are very few CP registers in low- and middle-income countries; however, recent estimates suggest that 34 900 children in low- and middle-income countries who were born in 2010 now have athetoid CP following kernicterus, even more have hearing loss and developmental delay 7. This is in stark contrast to countries such as Sweden and Australia. Staggering numbers, for a severe form of CP, and there are efforts underway to translate relatively inexpensive practices to prevent this preventable cause of CP for those in low- and middle-income countries 7. The pathway to CP that affects children born at near-term or term via hypoxic–ischaemic encephalopathy accounted for between 4 and 7 per cent of CP 3. There is hope that this pathway will reduce further through patient safety programs, nutritional supplements such as creatine (proving effective in animal models) and new treatment options such as therapeutic hypothermia plus adjuvant therapies 8. There is reason for optimism that, in high-income countries, these combinations will result in more babies with no impairments, less neonatal deaths, CP and less severe disability. This aetiological pathway is however one of the most important pathways to both neonatal death and long-term disability in low- income to middle-income countries where efforts to develop more inexpensive, scalable treatments will be required. Even within relatively new aetiological associations in high-income countries, there are changing trends, albeit more subtle. Assistive reproductive technology (ART) is one such area. The pathway to CP for those who also received ART was thought to be accounted for by plurality (multiple embryo transfer) and being born very premature. But a very recent paper identified an excess risk in those born as singletons and very premature 9. In this paper 3 with more recent birth years, the proportion of CP following ART remained the same at 5.6%, but there were only 2 of 11 children born less than 31 weeks, and only three of 11 were multiples, suggesting even a changing panorama of CP following ART. This is not the first time we have had this discussion in CP, in 1975, after Sweden reported its lowest ever prevalence their paper stated: ‘During recent years there has been much debate as to whether the incidence of CP has decreased or remained stationary…’ 4. Looking back over the last 50 years, we can see the epidemiology of CP has never been stationary and instead has been constantly changing, and this will no doubt continue into the future. Declines in prevalence even if short-lived must be celebrated and learnt from as they provide real-world evidence of the impact of advances in clinical practice particularly in response to newly identified causal pathways. Our aims should now be to (i) keep identifying and detailing the many small aetiological pathways to CP; (ii) keep testing new ways to prevent them, (iii) keep monitoring the outcomes in the real-world context of a population register using the many reliable classification tools we have available to us (e.g. gross motor, fine motor, communication and cognition). All this with an expectation of extending the decreases in prevalence and minimising the magnitude of any increases. Most importantly, we should be working with colleagues in low- and middle-income settings, where the great majority of children with disabilities live, to help identify strategies that will have the biggest impact for them.
No takes yet. Share an insight, caveat, or question.
Sarah McIntyre (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: